1. Home
  2. XIN vs CANF Comparison

XIN vs CANF Comparison

Compare XIN & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XIN
  • CANF
  • Stock Information
  • Founded
  • XIN 1997
  • CANF 1994
  • Country
  • XIN China
  • CANF Israel
  • Employees
  • XIN N/A
  • CANF N/A
  • Industry
  • XIN Homebuilding
  • CANF Biotechnology: Pharmaceutical Preparations
  • Sector
  • XIN Consumer Discretionary
  • CANF Health Care
  • Exchange
  • XIN Nasdaq
  • CANF Nasdaq
  • Market Cap
  • XIN 15.9M
  • CANF 14.4M
  • IPO Year
  • XIN N/A
  • CANF N/A
  • Fundamental
  • Price
  • XIN $2.41
  • CANF $1.46
  • Analyst Decision
  • XIN
  • CANF Strong Buy
  • Analyst Count
  • XIN 0
  • CANF 2
  • Target Price
  • XIN N/A
  • CANF $14.00
  • AVG Volume (30 Days)
  • XIN 28.3K
  • CANF 1.2M
  • Earning Date
  • XIN 01-01-0001
  • CANF 02-03-2025
  • Dividend Yield
  • XIN N/A
  • CANF N/A
  • EPS Growth
  • XIN N/A
  • CANF N/A
  • EPS
  • XIN N/A
  • CANF N/A
  • Revenue
  • XIN $667,143,185.00
  • CANF $667,000.00
  • Revenue This Year
  • XIN N/A
  • CANF $409.56
  • Revenue Next Year
  • XIN N/A
  • CANF N/A
  • P/E Ratio
  • XIN $0.27
  • CANF N/A
  • Revenue Growth
  • XIN N/A
  • CANF N/A
  • 52 Week Low
  • XIN $1.92
  • CANF $1.29
  • 52 Week High
  • XIN $7.05
  • CANF $4.69
  • Technical
  • Relative Strength Index (RSI)
  • XIN 33.59
  • CANF 38.71
  • Support Level
  • XIN $2.24
  • CANF $1.41
  • Resistance Level
  • XIN $2.59
  • CANF $1.54
  • Average True Range (ATR)
  • XIN 0.25
  • CANF 0.11
  • MACD
  • XIN -0.02
  • CANF 0.01
  • Stochastic Oscillator
  • XIN 10.34
  • CANF 47.60

About XIN Xinyuan Real Estate Co Ltd

Xinyuan Real Estate Co Ltd operates as a real estate developer and property manager in China. It focuses on developing residential projects, which typically consist of multiple residential buildings that include multi-layer apartment buildings, and others. Its several projects include auxiliary services and amenities such as retail outlets, leisure and health facilities, kindergartens, and schools. It aims to provide comfortable and convenient real estate-related products and services to middle-class consumers.

About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

Share on Social Networks: